- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06769048
Un estudio para probar diferentes dosis de BI 1584862 en personas con una forma distinta de degeneración macular relacionada con la edad (DMAE) llamada atrofia geográfica
JADE: ensayo de fase II en pacientes con atrofia geográfica: un estudio de búsqueda de dosis, aleatorizado, doble enmascarado, controlado con placebo para evaluar la eficacia y seguridad de BI 1584862
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.
Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Gilbert, Arizona, Estados Unidos, 85297
- Associated Retina Consultants
-
Phoenix, Arizona, Estados Unidos, 85020
- Associated Retina Consultants, Ltd.
-
Phoenix, Arizona, Estados Unidos, 85050
- Cameron Ria, LLC
-
Scottsdale, Arizona, Estados Unidos, 85255
- Retina Macula Institute of Arizona
-
-
California
-
Beverly Hills, California, Estados Unidos, 90211
- Retina-Vitreous Associates Medical Group
-
Glendale, California, Estados Unidos, 91204
- Global Research Management
-
Huntington Beach, California, Estados Unidos, 92647
- Retina Associates of Southern California
-
Modesto, California, Estados Unidos, 95356
- Retinal Consultants Medical Group, Inc
-
Mountain View, California, Estados Unidos, 94040
- Northern California Retina Vitreous Associates MedicalGroup, Inc.
-
Newport Beach, California, Estados Unidos, 92663
- Eye Research Foundation
-
Poway, California, Estados Unidos, 92064
- Retina Consultants of San Diego
-
Sacramento, California, Estados Unidos, 95825
- Retinal Consultants Medical Group
-
Walnut Creek, California, Estados Unidos, 94598
- Bay Area Retina Associates - Walnut Creek
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80222
- Retina Specialists of Colorado Research, LLC
-
-
Connecticut
-
Greenwich, Connecticut, Estados Unidos, 06830
- Coastal Eye Surgeons
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32605
- Vitreo Retinal Associates - Gainesville
-
Miami, Florida, Estados Unidos, 33143
- MedEye Associates
-
Pinellas Park, Florida, Estados Unidos, 33782
- Eye Associates of Pinellas
-
Stuart, Florida, Estados Unidos, 34994
- East Florida Eye Institute
-
Winter Haven, Florida, Estados Unidos, 33880
- Center for Retina and Macular Disease
-
-
Georgia
-
Augusta, Georgia, Estados Unidos, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Oak Park, Illinois, Estados Unidos, 60304
- Illinois Retina Associates - Oak Park
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40206
- The Eye Care Institute
-
-
Maryland
-
Hagerstown, Maryland, Estados Unidos, 21740
- Cumberland Valley Retina Consultants
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Ophthalmic Consultants of Boston
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65212
- University of Missouri Health System
-
-
New Jersey
-
Teaneck, New Jersey, Estados Unidos, 07666
- NJRetina
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Verum Research, LLC
-
Portland, Oregon, Estados Unidos, 97221
- Retina Northwest
-
Portland, Oregon, Estados Unidos, 97225
- EyeHealth Northwest
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Mid Atlantic Retina - Wills Eye Hospital
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29414
- Charleston Neuroscience Institute - Charleston
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Tennessee Retina
-
-
Texas
-
Austin, Texas, Estados Unidos, 78750
- Austin Clinical Research, LLC
-
Beaumont, Texas, Estados Unidos, 77707
- Retina Consultants of Texas - Beaumont
-
Dallas, Texas, Estados Unidos, 75231
- Retina Foundation of the Southwest
-
Plano, Texas, Estados Unidos, 75024
- Red River Research Partners, LLC - Plano
-
San Antonio, Texas, Estados Unidos, 78240
- Retinal Consultants of San Antonio
-
Schertz, Texas, Estados Unidos, 78154
- Retina Consultants of Texas - Schertz
-
The Woodlands, Texas, Estados Unidos, 77384
- Retina Consultants of Texas-The Woodlands-67575
-
-
Virginia
-
Falls Church, Virginia, Estados Unidos, 22042
- Emerson Clinical Research Institute
-
Lynchburg, Virginia, Estados Unidos, 24502
- Piedmont Eye Center
-
-
Washington
-
Bellevue, Washington, Estados Unidos, 98004
- Pacific Northwest Retina
-
-
-
-
-
Arecibo, Puerto Rico, 00612
- Emanuelli Research & Development Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
-
Men and women with at least 1 eye with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) determined by fundus autofluorescence (FAF). The total size of all GA lesions in the study eye (as determined by the independent central reading center (CRC)) must be ≥1.25 mm^2 and ≤12.0 mm^2:
- If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥0.5 mm^2
- At least 1 GA lesion must be at least in part within a 1500 μm radius ring centered on the fovea
- The foveal center point must not be involved in any atrophic lesion
- Lesion(s) must reside completely within the FAF image
-
Best corrected visual acuity (BCVA) score of ≥50 letters in the study eye using the early treatment diabetic retinopathy study (ETDRS) chart (approximately equivalent to ≥20/100 on the Snellen chart).
-
Hyperautofluorescence of any pattern, as assessed by the CRC, must be present in the junctional zone of GA in the study eye.
-
Age ≥50 years.
-
Men must be willing and able to use contraception (condom, abstinence) to prevent pregnancy and/or exposure of an existing embryo or fetus to the investigational product. A female participant is eligible if she is not a woman of childbearing potential.
-
Signed informed consent consistent with International Conference of Harmonization-Good Clinical Practice (ICH GCP) guidelines and local legislation
Exclusion criteria:
-
Any history of, or evidence of, exudative age-related macular degeneration (eAMD) in the study eye.
-
Previously received treatment for GA in the study eye within 4 months or 5 half-lives, prior to baseline, whichever is longer.
-
Previously received an investigational medication (oral or intravitreal) for GA within 4 months or 5 half-lives prior to baseline, whichever is longer.
-
Additional eye disease in the study eye that could compromise BCVA or significantly impact retinal morphology:
- uncontrolled glaucoma, defined as a disk-to-cup ratio >0.8 or ocular hypertension with intra ocular pressure (IOP) >24 mmHg at screening visit, or use of >2 active IOP-lowering agents in the study eye
- clinically significant diabetic retinopathy or maculopathy in the opinion of the investigator
- history of high myopia, i.e. spherical equivalent of ≥8 diopters or axial length ≥27.2 mm. Note: if subject had prior cataract or refractive surgery, spherical equivalent should be evaluated with pre-operative refraction. If axial length measurement is not available in medical records and cannot be obtained at screening visit, assessment of high myopia can be made by investigator on clinical examination.
- anterior segment and vitreous abnormalities that would preclude adequate observation with SD-OCT in the opinion of the investigator
- other ocular conditions at the discretion of the investigator that might interfere with the outcome of the trial
-
Significant disease or other medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator result in any of the following:
- put the participant at risk because of participation in the study
- influence the results of the study
- cause concern regarding the participant's ability to comply with the protocol requirements or complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant)
-
Known hypersensitivity to any of the ingredients used in the investigational medicinal product (IMP) formulation, or any of the medications used.
-
Active intraocular inflammation in the study eye.
-
Active infectious conjunctivitis in either eye. Further exclusion criteria apply.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: BI de combinación con placebo 1584862
|
Placebo-matching BI 1584862 |
|
Experimental: BI 1584862 dosis 1
|
BI 1584862 |
|
Experimental: BI 1584862 dosis 2
|
BI 1584862 |
|
Experimental: BI 1584862 dosis 3
|
BI 1584862 |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eye
Periodo de tiempo: Up to week 50.
|
mm is millimeters. |
Up to week 50.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Aparición de TEAES desde la administración del fármaco hasta la semana 52
Periodo de tiempo: Hasta la semana 52.
|
Hasta la semana 52.
|
|
|
Cambio desde el valor inicial en la atenuación parcial como porcentaje de la zona elipsoide (EZ) en el área macular con un espesor <20 microgramos (μm) hasta la semana 50 evaluado mediante tomografía volumétrica de coherencia óptica (OCT) en el ojo del estudio
Periodo de tiempo: Hasta la semana 50.
|
Hasta la semana 50.
|
|
|
Cambio desde el valor inicial en el área de atrofia geográfica (GA) transformada con raíz cuadrada medida por autofluorescencia del fondo de ojo (FAF) en la semana 50 (expresada en mm) en el ojo del estudio
Periodo de tiempo: Al inicio y en la semana 50.
|
Al inicio y en la semana 50.
|
|
|
Key secondary endpoint: Change from baseline in total attenuation as a percentage of the EZ at the macular area with a thickness of 0 μm up to week 50 assessed by volumetric OCT and EZ mapping in the study eye
Periodo de tiempo: Up to week 50.
|
EZ stands for ellipsoid zone. OCT stands for optical coherence tomography. |
Up to week 50.
|
|
Key secondary endpoint: Slope of change from baseline in square root transformed GA area as measured by OCT over a trial period of up to 50 weeks (expressed in mm/year) in the study eye
Periodo de tiempo: Up to week 50.
|
GA stands for geographic atrophy. OCT stands for optical coherence tomography. mm is millimeters. |
Up to week 50.
|
|
Occurrence of BCVA letter loss of ≥15 from baseline in the study eye as measured by standardized ETDRS chart for at least 2 consecutive visits between baseline and up to Week 50
Periodo de tiempo: Up to week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
Up to week 50.
|
|
Change from baseline in best-corrected low luminance visual deficit (LLVD) score as measured in letters by ETDRS chart under low-luminance conditions at Week 50 in the study eye
Periodo de tiempo: At baseline and at week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
At baseline and at week 50.
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 1484-0005
- U1111-1309-9115 (Identificador de registro: WHO International Clinical Trials Registry Platform (ICTRP))
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Marco de tiempo para compartir IPD
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Criterios de acceso compartido de IPD
For study documents - upon signing of a 'Document Sharing Agreement'.
For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .